Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Credit agrmnt [a]
Appointed director
Monthly oper. report

ACCENTIA BIOPHARMACEUTICALS INC (ABPI) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2015 SC 13G/A KCG AMERICAS LLC reports a 13.7% stake in Accentia Biopharmaceuticals, Inc.
02/09/2015 SC 13G KCG AMERICAS LLC reports a 7% stake in Accentia Biopharmaceuticals, Inc.
07/15/2013 8-K Quarterly results
03/07/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/22/2013 RW Form RW - Registration Withdrawal Request
02/22/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/14/2013 10-Q Quarterly Report for the period ended December 31, 2012
12/26/2012 10-K Annual Report for the period ended September 30, 2012
11/23/2012 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
10/15/2012 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
08/14/2012 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
08/14/2012 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
08/14/2012 10-Q Quarterly Report for the period ended June 30, 2012
08/14/2012 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "For further information, please visit: http://www.biovest.com Forward-Looking Statements: Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to, statements about Biovest and its product candidate, BiovaxID™ and any other statements relating to products, product candidates, product development programs, the FDA, the EMA, Health Canada or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as “may,” “could,” “would,” “should,” “believe..."
07/11/2012 EFFECT Form EFFECT - Notice of Effectiveness
06/27/2012 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
06/21/2012 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of Subscription Agreement",
"Form of Common Stock Purchase Warrant"
06/07/2012 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Secured Promissory Note, in the original principal amount of $1,500,000 payable by Accentia Biopharmaceuticals, Inc. to Pabeti, Inc",
"Common Stock Purchase Warrant, issued by Accentia Biopharmaceuticals, Inc. to Pabeti, Inc",
"Security Agreement, by Accentia Biopharmaceuticals, Inc. in favor of Pabeti, Inc",
"Amendment No. 1 to Plan Convertible Promissory Note, between Accentia Biopharmaceuticals, Inc. and Dennis Ryll"
05/15/2012 10-Q Quarterly Report for the period ended March 31, 2012
04/13/2012 8-K/A Form 8-K - Current report [amend]
03/15/2012 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933 [Amend]
03/08/2012 8-K Submission of Matters to a Vote of Security Holders
02/10/2012 10-Q Quarterly Report for the period ended December 31, 2011
02/01/2012 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/20/2012 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
01/20/2012 DEF 14A Form DEF 14A - Other definitive proxy statements
12/19/2011 10-K Annual Report for the period ended September 30, 2011
11/07/2011 8-K Form 8-K - Current report
11/04/2011 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
09/20/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Accentia Biopharmaceuticals Joins National Organization for Rare Disorders Corporate Council"
09/14/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Accentia Biopharmaceuticals Announces that FDA Grants Orphan Drug Status for Revimmune™ Therapy for the Prevention of Graft-Versus-Host Disease in Bone Marrow Transplant TAMPA, FL - September 14, 2011 - Accentia Biopharmaceuticals, Inc. and its majority-owned subsidiary, Biovest International, Inc. , today jointly announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Revimmune™, the Company's proprietary system-of-care based on high-dose administration of Cytoxan® , for the prevention of graft-versus-host disease following bone marrow transplant. GVHD is a life-threatening autoimmune complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted cells trigger an immune attack on the transplant recipient's body. ..."
08/12/2011 10-Q Quarterly Report for the period ended June 30, 2011
06/24/2011 8-K Form 8-K - Current report
06/23/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Accentia Biopharmaceuticals Announces that FDA grants Orphan Drug Status for Revimmune™ Therapy for the Treatment of Two Autoimmune Diseases: Systemic Sclerosis & Hemolytic Anemia TAMPA, FL - June 23, 2011 - Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Revimmune™, the Company's proprietary system-of-care based on high-dose administration of Cytoxan® , for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia. Based on an exclusive world-wide license from Johns Hopkins University and a strategic agreement with Baxter Corporation, Accentia intends to conduct multiple clinical trials evaluating Revimmune therapy for the treatment of a range of autoimmune dis..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy